April 15, 2010 09:36 ET

EASL 2010: To Broaden Access to Examinations, Echosens, a World Leader in Elastography, Presents an Addition to Its Fibroscan® Product Line

VIENNA, AUSTRIA--(Marketwire - April 15, 2010) - On the occasion of the 2010 edition of the European Association for the Study of the Liver (EASL) conference, Echosens, a pioneer and major player in the field of non-invasive hepatology diagnosis, introduces its new research and development focus with the launching of the latest addition to the Echosens product line, the FibroScan® 402. 

Facilitating access to quantification of hepatic fibrosis

In creating the FibroScan® 502 and its dedicated probes and commercializing the product since 2004, Echosens opened a new market for medical hepatology devices. This first version of the Fibroscan® answered the needs of both doctors and patients, providing them with a reliable, non-invasive way to evaluate hepatic fibrosis. 

The fruit of Echosens research and development, the Fibroscan® 402 will enable the medical community to provide a larger number of patient with access to this technology. 

Extremely simple to start and operate, the Fibroscan® 402 works in "plug and play" mode. Following "remote training" via the Web, doctors need only connect their device to provide this examination to their patients. 

Compact, lightweight and easy to handle, the Fibroscan® 402 answers the needs of city doctors, nearby hospitals and clinics . By enlarging its product line, Echosens initiates the transfer of this technology from the hospital toward the city . These parameters also enable its acquisition by previously unequipped institutions such as prisons, specialized health-care centers and gastroenterology practices. 

With integrated direct printing, doctors can provide on-the-spot examination results to their patients with no unnecessary delays. For patients, it guarantees results in hand before they leave the doctor's premises. 

Echosens innovates and diversifies its research focus

In recent years cases of metabolic diseases (type 2 diabetes, obesity) have exploded, both in France and around the world. These pathologies generate multiple complications such as non-alcoholic hepatic steatosis. This conference also constitutes an opportunity to present a new application in elastography, the CAP™, which evaluates liver steatosis . 

This new technological development represents part of Echosens's strong intellectual property policy. 

About Echosens and Fibroscan®

FibroScan® is designed to quantify hepatic elasticity in a non-invasive manner in the evaluation of chronic liver diseases such as viral hepatitis B and C. 

Founded in 2004, Echosens dedicates a major portion of its activity to research and development in order to invent new medical devices and open up new medical perspectives. The organization works in close cooperation with health professionals and patients' associations to facilitate management and therapeutic monitoring of patients. 

Contact Information